COAG HEMAB THERAPEUTICS HLDGS INC revenue, earnings and financials
For the quarter ended June 30, 2026, HEMAB THERAPEUTICS HLDGS INC reported revenue of n/a, net income of −$24.2M and diluted EPS of −$0.80.
COAG quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$24.2M, EPS −$0.80
- Quarter ended Mar 31, 2026: revenue n/a, net income −$22.7M, EPS −$23.98
- Quarter ended Jun 30, 2025: revenue n/a, net income −$12.2M, EPS −$12.91
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.3M, EPS −$16.18
COAG balance sheet
- Jun 30, 2026: cash $237M, total assets $468M, total liabilities $13.5M, shareholders' equity $454M
- Mar 31, 2026: cash $49.9M, total assets $175M, total liabilities $13.7M, shareholders' equity −$199M
- Dec 31, 2025: cash $88.0M, total assets $195M, total liabilities $11.3M, shareholders' equity −$177M